KOSPI biosimilar leader
Celltrion
Celltrion is a global biopharma that has won marketing approval for 11 biosimilars, starting with Remsima (CT-P13), the world's first monoclonal-antibody biosimilar. Alongside Remsima, Truxima, Herzuma, Yuflyma and Vegzelma, it directly sells Zymfentra (Remsima SC), the world's first subcutaneous infliximab, in the United States. After absorbing Celltrion Healthcare in December 2023 it unified development, manufacturing and sales, and shifted its entire portfolio to a direct-sales model in Europe and the US. FY2025 consolidated revenue was KRW 4.16tn with operating profit of KRW 1.17tn.
068270.KS Updated Jul 12, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Celltrion is directly linked to 1 companies (1 supply, 0 revenue relationships) and reaches 1 companies within two hops; the links are backed by 3 dated sources, 1 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · KRW 4.16tn (FY2025 consolidated)
- Segments · Biopharmaceuticals · Chemical drugs and other
Revenue from
- 유럽 처방시장 (직접판매) High confidence· Amount 2,009,681 KRW_mn · FY2025 · Consolidated external revenue by region (Europe), net of intercompany
Largest overseas market. FY2025 external European revenue ~KRW 2.0tn. Remsima holds 59% EU share (IQVIA Q3 2025), Remsima SC 30% of EU5. Direct-sales conversion of the full portfolio completed H2 2022. - 미국·북미 처방시장 (짐펜트라 직접판매) High confidence· Amount 419,963 KRW_mn · FY2025 · Consolidated external revenue by region (North America), +150% vs KRW 168,086mn prior year
Fast-growing market. FY2025 external North America revenue ~KRW 420bn (+150% vs KRW 168bn prior year). Sells Zymfentra, the world's first SC infliximab, directly; ~31% avg monthly prescription growth since the March 2024 launch, and January 2026 prescriptions roughly tripled (+213%) YoY.Mentions KO Newspim (DS Investment & Securities) Published May 7, 2026: Celltrion: Omlyclo, Stoboclo surge; DS Investment maintains KRW 320k targetConfirms EN Seoul Economic Daily (English) Published Mar 19, 2026: Celltrion's Zymfentra Posts Record U.S. Prescriptions in January - 국내 처방시장 (셀트리온제약·Primary Care) Medium confidence· Amount 1,262,073 KRW_mn · FY2025 · Consolidated external revenue by region (Korea), net of intercompany
FY2025 external domestic revenue ~KRW 1.26tn, including Celltrion Pharm Cheongju chemical output and Takeda-acquired Primary Care brands (Nesina, Actos for diabetes; Edarbi for hypertension).
Pays to
- 세포배양 배지·바이오의약품 원재료 공급망 High confidence· Amount 345,744 KRW_mn · FY2025 · Consolidated raw-material purchases (biopharma, 68.42% of total)
Largest FY2025 purchase category. Biopharma raw materials (cell-culture media etc.) KRW 345.7bn (68.42% of purchases) plus sub-materials (CIP 100 etc.) KRW 49.2bn. Sourced build-to-order; key suppliers undisclosed for competitive/contractual reasons. - 케미컬의약품 원료 공급망 (오로트산카르니틴 등) High confidence· Amount 110,421 KRW_mn · FY2025 · Consolidated raw-material purchases (chemical drugs, 21.85% of total)
FY2025 chemical-drug raw materials (orotic acid carnitine etc.) KRW 110.4bn (21.85% of purchases) for Celltrion Pharm Cheongju small-molecule production. Suppliers undisclosed. - AbbVie Medium confidence
Yuflyma (CT-P17) is a biosimilar of AbbVie's originator Humira. To launch in the US in 2023, Celltrion completed a patent agreement with AbbVie (biosimilar patent settlements typically carry royalty payments). Amount undisclosed.
Investments
- Kaigene, Inc. (희귀 자가면역 신약 라이선스-인) Medium confidence· contract 8 USD_mn · 2025-11-04~ · License-in upfront $8M (dev up to $111M, sales up to $625M, royalty 5-10%)
On 2025-11-04 Celltrion signed a license-in deal with US-based Kaigene for a rare autoimmune drug candidate: $8M upfront (~KRW 11.4bn), up to $111M development milestones, up to $625M sales milestones (at $4bn net sales), and 5-10% royalties. Part of its push into next-gen modalities (ADC, bispecifics).
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Celltrion | node | -52.3 | +13 | +10.1 | +5.4 | +22 | -12.4 |
| AbbVie | benef1 | +32.4 | +24 | -0.2 | +18.9 | +33.1 | +10.4 |
YTD as of 2026-07-10 · source: Yahoo Finance
Celltrion's thesis is a shift from the world's biosimilar leader toward higher margin and pipeline via direct sales and novel drugs. Starting with Remsima, the world's first antibody biosimilar, it has won 11 approvals and posted FY2025 consolidated revenue of KRW 4.16tn and operating profit of KRW 1.17tn (28% margin). Absorbing Celltrion Healthcare in 2023 to unify development, manufacturing and sales and converting the full portfolio to direct sales in Europe and the US is the margin-lift axis — if Europe's 59% Remsima share is the cash base, the growth trigger is the US. It directly sells Zymfentra (Remsima SC), the world's first subcutaneous infliximab, driving North American revenue up +150% (January 2026 prescriptions +213%). Deals like the Kaigene license-in push into novel modalities (ADC, bispecifics) to prepare for life beyond biosimilars. Re-rating triggers are Zymfentra US penetration, new biosimilar launches, and pipeline progress.
Analysis generated from returns as of 2026-07-10